Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.
Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
St George Hospital; Cancer Care Centre, Kogarah, New South Wales, Australia
Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
Ochsner Medical Center Kenner, Kenner, Louisiana, United States
Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States
Allegiance Health, Jackson, Michigan, United States
Princess Margaret Cancer Center, Toronto, Ontario, Canada
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, Japan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Baylor College of Medicine, Houston, Texas, United States
Fred Hutchinson Cancer Research Center - University of Washington, Seattle, Washington, United States
Institut Curie; Oncologie Medicale, Paris, France
Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
MD Anderson, Houston, Texas, United States
Yale University Smilow Cancer Hospital, New Haven, Connecticut, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.